Clinical trial BGB-A317-306
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
| Cancers | |
|---|---|
| Organ | Esophagus |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BeiGene |
| EudraCT Identifier | 2018-000587-28 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03783442 |
| Inclusion criteria | Stage IV unresecable ESCC. Measurable or evaluable disease (RECIST v1.1). ECOG Performance Status ? 1. Adequate organ function. Newly obtained or archival tissue sample available. |
| Last update |